BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kotb MA. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012;13:8882-914. [PMID: 22942741 DOI: 10.3390/ijms13078882] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Yu H, Liu C, Wang J, Han J, Zhang F, Zhou X, Wen Y, Shen T. miRNA and miRNA target genes in intervention effect of Zhuyu pill on cholestatic rat model. J Ethnopharmacol 2022;283:114709. [PMID: 34626777 DOI: 10.1016/j.jep.2021.114709] [Reference Citation Analysis]
2 Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 2021:S0016-5085(21)03707-0. [PMID: 34757143 DOI: 10.1053/j.gastro.2021.10.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
3 Gao L, Wang L, Woo E, He X, Yang G, Bowlus C, Leung PSC, Gershwin ME. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. Clin Rev Allergy Immunol. 2019;. [PMID: 31713023 DOI: 10.1007/s12016-019-08772-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Han YH, Jeong HJ, Kim EM, Boud F, Lim ST, Lee SY, Sohn MH. Effect of Ursodeoxycholic Acid on the Biodistribution and Excretion of Technetium-99m Radiopharmaceuticals in Rat: A Potential Image Quality Enhancer. Yonsei Med J 2021;62:555-62. [PMID: 34027643 DOI: 10.3349/ymj.2021.62.6.555] [Reference Citation Analysis]
5 Li H, Guan Y, Han C, Zhang Y, Liu Q, Wei W, Ma Y. The pathogenesis, models and therapeutic advances of primary biliary cholangitis. Biomed Pharmacother 2021;140:111754. [PMID: 34044277 DOI: 10.1016/j.biopha.2021.111754] [Reference Citation Analysis]
6 Huang K, Liu C, Peng M, Su Q, Liu R, Guo Z, Chen S, Li Z, Chang G. Glycoursodeoxycholic Acid Ameliorates Atherosclerosis and Alters Gut Microbiota in Apolipoprotein E-Deficient Mice. J Am Heart Assoc 2021;10:e019820. [PMID: 33787322 DOI: 10.1161/JAHA.120.019820] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Doden HL, Ridlon JM. Microbial Hydroxysteroid Dehydrogenases: From Alpha to Omega. Microorganisms 2021;9:469. [PMID: 33668351 DOI: 10.3390/microorganisms9030469] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
8 Tran QT, Tran VH, Sendler M, Doller J, Wiese M, Bolsmann R, Wilden A, Glaubitz J, Modenbach JM, Thiel FG, de Freitas Chama LL, Weiss FU, Lerch MM, Aghdassi AA. Role of Bile Acids and Bile Salts in Acute Pancreatitis: From the Experimental to Clinical Studies. Pancreas 2021;50:3-11. [PMID: 33370017 DOI: 10.1097/MPA.0000000000001706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Arai Y, Park H, Park S, Kim D, Baek I, Jeong L, Kim BJ, Park K, Lee D, Lee SH. Bile acid-based dual-functional prodrug nanoparticles for bone regeneration through hydrogen peroxide scavenging and osteogenic differentiation of mesenchymal stem cells. J Control Release 2020;328:596-607. [PMID: 32946872 DOI: 10.1016/j.jconrel.2020.09.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Shoaib M, Choudhary RC, Choi J, Kim N, Hayashida K, Yagi T, Yin T, Nishikimi M, Stevens JF, Becker LB, Kim J. Plasma metabolomics supports the use of long-duration cardiac arrest rodent model to study human disease by demonstrating similar metabolic alterations. Sci Rep 2020;10:19707. [PMID: 33184308 DOI: 10.1038/s41598-020-76401-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu SP, Bian ZH, Zhao ZB, Wang J, Zhang W, Leung PSC, Li L, Lian ZX. Animal Models of Autoimmune Liver Diseases: a Comprehensive Review. Clin Rev Allergy Immunol 2020;58:252-71. [PMID: 32076943 DOI: 10.1007/s12016-020-08778-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Firus Khan AY, Ahmed QU, Nippun TS, Hilles A, Jalal TK, Teh LK, Salleh MZ, Noor SM, Seeni A, Khatib A, Wahab RA. Determination toxic effects of Hystrix Brachyura Bezoar extracts using cancer cell lines and embryo zebrafish (Danio rerio) models and identification of active principles through GC-MS analysis. J Ethnopharmacol 2020;262:113138. [PMID: 32726681 DOI: 10.1016/j.jep.2020.113138] [Reference Citation Analysis]
13 Pérez A, Rivoira MA, Rodríguez V, Marchionatti A, Tolosa de Talamoni N. Role of mitochondria in the differential action of sodium deoxycholate and ursodeoxycholic acid on rat duodenum. Can J Physiol Pharmacol 2021;99:270-7. [PMID: 32687730 DOI: 10.1139/cjpp-2019-0561] [Reference Citation Analysis]
14 Martinefski MR, Rodriguez MR, Buontempo F, Lucangioli SE, Bianciotti LG, Tripodi VP. Coenzyme Q 10 supplementation: A potential therapeutic option for the treatment of intrahepatic cholestasis of pregnancy. Eur J Pharmacol 2020;882:173270. [PMID: 32534074 DOI: 10.1016/j.ejphar.2020.173270] [Reference Citation Analysis]
15 Ali FEM, Hassanein EHM, Bakr AG, El-Shoura EAM, El-Gamal DA, Mahmoud AR, Abd-Elhamid TH. Ursodeoxycholic acid abrogates gentamicin-induced hepatotoxicity in rats: Role of NF-κB-p65/TNF-α, Bax/Bcl-xl/Caspase-3, and eNOS/iNOS pathways. Life Sci 2020;254:117760. [PMID: 32418889 DOI: 10.1016/j.lfs.2020.117760] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
16 Li DS, Huang QF, Guan LH, Zhang HZ, Li X, Fu KL, Chen YX, Wan JB, Huang M, Bi HC. Targeted bile acids and gut microbiome profiles reveal the hepato-protective effect of WZ tablet (Schisandra sphenanthera extract) against LCA-induced cholestasis. Chin J Nat Med 2020;18:211-8. [PMID: 32245591 DOI: 10.1016/S1875-5364(20)30023-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kusaczuk M. Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives. Cells 2019;8:E1471. [PMID: 31757001 DOI: 10.3390/cells8121471] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
18 Goossens J, Bailly C. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy. Pharmacology & Therapeutics 2019;203:107396. [DOI: 10.1016/j.pharmthera.2019.107396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
19 Athauda D, Foltynie T. Drug Repurposing in Parkinson's Disease. CNS Drugs 2018;32:747-61. [PMID: 30066310 DOI: 10.1007/s40263-018-0548-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
20 Tanaka M, Sanefuji M, Morokuma S, Yoden M, Momoda R, Sonomoto K, Ogawa M, Kato K, Nakayama J. The association between gut microbiota development and maturation of intestinal bile acid metabolism in the first 3 y of healthy Japanese infants. Gut Microbes 2020;11:205-16. [PMID: 31550982 DOI: 10.1080/19490976.2019.1650997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
21 Zhou D, Kong L, Jiang Y, Wang C, Ni Y, Wang Y, Zhang H, Ruan J. UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chemico-Biological Interactions 2019;310:108745. [DOI: 10.1016/j.cbi.2019.108745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Oliveira CP, Cotrim HP, Stefano JT, Siqueira ACG, Salgado ALA, Parise ER. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. Arq Gastroenterol 2019;56:184-90. [PMID: 31460584 DOI: 10.1590/S0004-2803.201900000-36] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Littlefield A, Lenahan C. Cholelithiasis: Presentation and Management. J Midwifery Womens Health 2019;64:289-97. [PMID: 30908805 DOI: 10.1111/jmwh.12959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sato K, Meng F, Fava G, Glaser S, Alpini G. Functional roles of gut bacteria imbalance in cholangiopathies. Liver Research 2019;3:40-5. [DOI: 10.1016/j.livres.2018.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
25 Kim YH, Kim JH, Kim BG, Lee KL, Kim JW, Koh S. Tauroursodeoxycholic acid attenuates colitis-associated colon cancer by inhibiting nuclear factor kappaB signaling: Effects of TUDCA in colitis. Journal of Gastroenterology and Hepatology 2019;34:544-51. [DOI: 10.1111/jgh.14526] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
26 Yu H, Fu QR, Huang ZJ, Lin JY, Chen QX, Wang Q, Shen DY. Apoptosis induced by ursodeoxycholic acid in human melanoma cells through the mitochondrial pathway. Oncol Rep 2019;41:213-23. [PMID: 30542709 DOI: 10.3892/or.2018.6828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Qiu JL, Shao MY, Xie WF, Li Y, Yang HD, Niu MM, Xu H. Effect of combined ursodeoxycholic acid and glucocorticoid on the outcome of Kasai procedure: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12005. [PMID: 30170405 DOI: 10.1097/MD.0000000000012005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Kim SH, Chun HJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Lee HS, Um SH, Kim CD. Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model. Oncol Lett 2018;16:2585-90. [PMID: 30008943 DOI: 10.3892/ol.2018.8893] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
29 El Awdan SA, Amin MM, Hassan A. Cilostazol attenuates indices of liver damage induced by thioacetamide in albino rats through regulating inflammatory cytokines and apoptotic biomarkers. European Journal of Pharmacology 2018;822:168-76. [DOI: 10.1016/j.ejphar.2018.01.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
30 Catzola A, Vajro P. Management options for cholestatic liver disease in children. Expert Review of Gastroenterology & Hepatology 2017;11:1019-30. [DOI: 10.1080/17474124.2017.1359538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
31 Kim EK, Cho JH, Kim E, Kim YJ. Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth. PLoS One. 2017;12:e0181183. [PMID: 28708871 DOI: 10.1371/journal.pone.0181183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
32 Uppala JK, Gani AR, Ramaiah KVA. Chemical chaperone, TUDCA unlike PBA, mitigates protein aggregation efficiently and resists ER and non-ER stress induced HepG2 cell death. Sci Rep 2017;7:3831. [PMID: 28630443 DOI: 10.1038/s41598-017-03940-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
33 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
34 Nipanikar SU, Chitlange SS, Nagore D. Pharmacological Evaluation of Hepatoprotective Activity of AHPL/AYTAB/0613 Tablet in Carbon Tetrachloride-, Ethanol-, and Paracetamol-Induced Hepatotoxicity Models in Wistar Albino Rats. Pharmacognosy Res 2017;9:S41-7. [PMID: 29333041 DOI: 10.4103/pr.pr_44_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
35 Wang Y, Mei X, Yuan J, Lai X, Xu D. Taurine zinc solid dispersions enhance bile-incubated L02 cell viability and improve liver function by inhibiting ERK2 and JNK phosphorylation during cholestasis. Toxicology 2016;366-367:10-9. [PMID: 27501764 DOI: 10.1016/j.tox.2016.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Agarwal DS, Anantaraju HS, Sriram D, Yogeeswari P, Nanjegowda SH, Mallu P, Sakhuja R. Synthesis, characterization and biological evaluation of bile acid-aromatic/heteroaromatic amides linked via amino acids as anti-cancer agents. Steroids 2016;107:87-97. [PMID: 26748355 DOI: 10.1016/j.steroids.2015.12.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
37 Ozel Coskun BD, Yucesoy M, Gursoy S, Baskol M, Yurci A, Yagbasan A, Doğan S, Baskol G. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2015;27:142-9. [PMID: 25533429 DOI: 10.1097/MEG.0000000000000264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
38 Drapkina OM, Bueverova EL. [Ursodeoxycholic acid: A therapeutic niche in an internist's practice]. Ter Arkh 2015;87:84-90. [PMID: 26087640 DOI: 10.17116/terarkh201587484-90] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 2015;63:952-61. [PMID: 26044126 DOI: 10.1016/j.jhep.2015.05.023] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
40 Vang S, Longley K, Steer CJ, Low WC. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med 2014;3:58-69. [PMID: 24891994 DOI: 10.7453/gahmj.2014.017] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 12.1] [Reference Citation Analysis]
41 Alhumaidha KA, El-awdan SA, El-iraky WI, El-denshary ES. Protective effects of ursodeoxycholic acid on ceftriaxone-induced hepatic injury in rats. Bulletin of Faculty of Pharmacy, Cairo University 2014;52:45-50. [DOI: 10.1016/j.bfopcu.2014.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
42 Vaz AR, Cunha C, Gomes C, Schmucki N, Barbosa M, Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol Neurobiol 2015;51:864-77. [PMID: 24848512 DOI: 10.1007/s12035-014-8731-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
43 Ozkol HU, Calka O, Dulger AC, Bulut G. Ursodeoxycholic acid induced generalized fixed drug eruption. Cutan Ocul Toxicol 2014;33:256-8. [PMID: 24147950 DOI: 10.3109/15569527.2013.838253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. [PMID: 24053454 DOI: 10.1186/1471-230x-13-140] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
45 Vajro P, Paolella G, Pierri L, D’Aniello R. Treatment of NASH with ursodeoxycholic acid: pros and cons. More information in children. Clin Res Hepatol Gastroenterol. 2013;37:e93-e94. [PMID: 23562789 DOI: 10.1016/j.clinre.2013.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]